JP Patent

JP7433252B2 — Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤

Assigned to キャンディ・セラピューティクス・リミテッド · Expires 2024-02-19 · 2y expired

What this patent protects

Patent listed against elinzanetant.

Drugs covered by this patent

Patent Metadata

Patent number
JP7433252B2
Jurisdiction
JP
Classification
—
Expires
2024-02-19
Drug substance claim
No
Drug product claim
No
Assignee
キャンディ・セラピューティクス・リミテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.